Source: Google NewsPublished on 2022-08-03
Related Articles:
- The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
- Older Parkinson’s Patients Often Wrongly Given Antipsychotics, Study Says March 2, 2020 More than one-third of older people with Parkinson’s disease in long-term care who experienced therapy-related psychosis were prescribed antipsychotic medications considered inappropriate under current guidelines, a study found. Those with dementia or using antidepressants were more likely to be given these medicines. Concerted efforts are needed to curb the use of inappropriate antipsychotics, which may worsen Parkinsonian symptoms, the researchers…
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries June 15, 2022 Am J Psychiatry. 2022 Jun 15:appiajp21090876. doi: 10.1176/appi.ajp.21090876. Online ahead of print.ABSTRACTOBJECTIVE: Pimavanserin, a serotonin 5-HT2 antagonist, is indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In premarketing trials in patients with Parkinson's disease psychosis, 11% of patients died during open-label pimavanserin treatment. Antipsychotics, which are used off-label in Parkinson's disease psychosis, increase mortality in dementia…
- Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries June 15, 2022 Am J Psychiatry. 2022 Jun 15:appiajp21090876. doi: 10.1176/appi.ajp.21090876. Online ahead of print.ABSTRACTOBJECTIVE: Pimavanserin, a serotonin 5-HT2 antagonist, is indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In premarketing trials in patients with Parkinson's disease psychosis, 11% of patients died during open-label pimavanserin treatment. Antipsychotics, which are used off-label in Parkinson's disease psychosis, increase mortality in dementia…
- Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries June 15, 2022 Am J Psychiatry. 2022 Jun 15:appiajp21090876. doi: 10.1176/appi.ajp.21090876. Online ahead of print.ABSTRACTOBJECTIVE: Pimavanserin, a serotonin 5-HT2 antagonist, is indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In premarketing trials in patients with Parkinson's disease psychosis, 11% of patients died during open-label pimavanserin treatment. Antipsychotics, which are used off-label in Parkinson's disease psychosis, increase mortality in dementia…
- Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries June 15, 2022 Am J Psychiatry. 2022 Jun 15:appiajp21090876. doi: 10.1176/appi.ajp.21090876. Online ahead of print.ABSTRACTOBJECTIVE: Pimavanserin, a serotonin 5-HT2 antagonist, is indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In premarketing trials in patients with Parkinson's disease psychosis, 11% of patients died during open-label pimavanserin treatment. Antipsychotics, which are used off-label in Parkinson's disease psychosis, increase mortality in dementia…
- Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries June 15, 2022 Am J Psychiatry. 2022 Jun 15:appiajp21090876. doi: 10.1176/appi.ajp.21090876. Online ahead of print.ABSTRACTOBJECTIVE: Pimavanserin, a serotonin 5-HT2 antagonist, is indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In premarketing trials in patients with Parkinson's disease psychosis, 11% of patients died during open-label pimavanserin treatment. Antipsychotics, which are used off-label in Parkinson's disease psychosis, increase mortality in dementia…
- Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries June 15, 2022 Am J Psychiatry. 2022 Jun 15:appiajp21090876. doi: 10.1176/appi.ajp.21090876. Online ahead of print.ABSTRACTOBJECTIVE: Pimavanserin, a serotonin 5-HT2 antagonist, is indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In premarketing trials in patients with Parkinson's disease psychosis, 11% of patients died during open-label pimavanserin treatment. Antipsychotics, which are used off-label in Parkinson's disease psychosis, increase mortality in dementia…
- New Phase 3 Trial to Test Nuplazid for Parkinson’s Psychosis in Array of Dementia Patients October 5, 2017 Acadia Pharmaceuticals is starting a new Phase 3 clinical trial testing the efficacy of pimavanserin to treat the hallucinations and delusions associated with dementia-related psychosis in a broad array of patients with Parkinson’s, Alzheimer’s, and many other dementias. Pimavanserin, under the brand name Nuplazid, was approved by the U.S. Food and Drug Administration (FDA) to treat dementia-related psychosis in Parkinson’s patients in 2016. This trial, and the Breakthrough…
- Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study October 31, 2021 Drugs Real World Outcomes. 2021 Oct 30. doi: 10.1007/s40801-021-00284-1. Online ahead of print.ABSTRACTBACKGROUND: Parkinson's disease-related psychosis increases patients' risk of falls. Pimavanserin is an atypical antipsychotic approved in the USA in 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease-related psychosis.OBJECTIVE: We aimed to compare the risk of falls/fractures among patients with Parkinson's disease-related psychosis treated with…
- Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study October 31, 2021 Drugs Real World Outcomes. 2021 Oct 30. doi: 10.1007/s40801-021-00284-1. Online ahead of print.ABSTRACTBACKGROUND: Parkinson's disease-related psychosis increases patients' risk of falls. Pimavanserin is an atypical antipsychotic approved in the USA in 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease-related psychosis.OBJECTIVE: We aimed to compare the risk of falls/fractures among patients with Parkinson's disease-related psychosis treated with…
- Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study October 31, 2021 Drugs Real World Outcomes. 2021 Oct 30. doi: 10.1007/s40801-021-00284-1. Online ahead of print.ABSTRACTBACKGROUND: Parkinson's disease-related psychosis increases patients' risk of falls. Pimavanserin is an atypical antipsychotic approved in the USA in 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease-related psychosis.OBJECTIVE: We aimed to compare the risk of falls/fractures among patients with Parkinson's disease-related psychosis treated with…
- Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study October 31, 2021 Drugs Real World Outcomes. 2021 Oct 30. doi: 10.1007/s40801-021-00284-1. Online ahead of print.ABSTRACTBACKGROUND: Parkinson's disease-related psychosis increases patients' risk of falls. Pimavanserin is an atypical antipsychotic approved in the USA in 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease-related psychosis.OBJECTIVE: We aimed to compare the risk of falls/fractures among patients with Parkinson's disease-related psychosis treated with…
- Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis May 31, 2021 J Manag Care Spec Pharm. 2021 Jun;27(6):785-790. doi: 10.18553/jmcp.2021.27.6.785.ABSTRACTBACKGROUND: Pimavanserin is approved for treatment of Parkinson disease (PD)-related psychosis, but its use has been associated with an increased risk of death during clinical trials, as well as during postmarketing surveillance. Previous reports on the association between pimavanserin and mortality have not taken into account limitations of data sources nor included…
- Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis May 31, 2021 J Manag Care Spec Pharm. 2021 Jun;27(6):785-790. doi: 10.18553/jmcp.2021.27.6.785.ABSTRACTBACKGROUND: Pimavanserin is approved for treatment of Parkinson disease (PD)-related psychosis, but its use has been associated with an increased risk of death during clinical trials, as well as during postmarketing surveillance. Previous reports on the association between pimavanserin and mortality have not taken into account limitations of data sources nor included…
- Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis May 31, 2021 J Manag Care Spec Pharm. 2021 Jun;27(6):785-790. doi: 10.18553/jmcp.2021.27.6.785.ABSTRACTBACKGROUND: Pimavanserin is approved for treatment of Parkinson disease (PD)-related psychosis, but its use has been associated with an increased risk of death during clinical trials, as well as during postmarketing surveillance. Previous reports on the association between pimavanserin and mortality have not taken into account limitations of data sources nor included…
- Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis May 31, 2021 J Manag Care Spec Pharm. 2021 Jun;27(6):785-790. doi: 10.18553/jmcp.2021.27.6.785.ABSTRACTBACKGROUND: Pimavanserin is approved for treatment of Parkinson disease (PD)-related psychosis, but its use has been associated with an increased risk of death during clinical trials, as well as during postmarketing surveillance. Previous reports on the association between pimavanserin and mortality have not taken into account limitations of data sources nor included…
- ‘Inappropriate’ Antipsychotics to Treat Depression in Elderly Parkinson’s Patients Linked to Pneumonia Risk November 6, 2019 Inappropriate antipsychotic medications — those approved for ills like schizophrenia but used to treat depression — given to elderly people with Parkinson’s disease increase their risk of pneumonia, a study suggests. The study, “Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson’s disease,” was published in the Journal of Psychiatric Research. Certain antipsychotic medications can be prescribed…
- Nuplazid Eases Depression in Parkinson’s Patients, Phase 2 Trial Shows October 1, 2019 Treatment with Nuplazid (pimavanserin), approved in the U.S. for treating hallucinations and delusions associated with Parkinson’s psychosis, eased depression and sleep problems in patients with Parkinson’s, according to results from a Phase 2 clinical trial. The research, “Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression,” was presented at the 2019 International Congress of Parkinson’s Disease and Movement Disorders in Nice,…
- FDA Rejects Pimavanserin sNDA for Dementia-Related Psychosis April 8, 2021 The Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Acadia Pharmaceuticals regarding the supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis. The sNDA submission was supported by data from the pivotal phase 3 HARMONY study (ClinicalTrials.gov: NCT03325556) that compared the efficacy and safety of pimavanserin,…